<DOC>
	<DOCNO>NCT00012467</DOCNO>
	<brief_summary>The purpose study examine antifungal activity recombinant interferon-gamma 1b ( rIFN-gamma 1b ) give standard antifungal therapy .</brief_summary>
	<brief_title>Safety Antifungal Activity Recombinant Interferon-Gamma 1b ( rIFN-Gamma 1b ) Given With Standard Therapy Patients With Cryptococcal Meningitis</brief_title>
	<detailed_description>Patients randomize 1 3 parallel group 3-arm , 2-stage , double-blind dose-ranging study 14 week . In Stage 1 , patient hospitalize 14 day acute therapy . Patients receive rIFN-gamma 1b placebo sc 3 time per week , intravenous ( IV ) AMB daily , without oral 5-FC every 6 hour . Patients ability take oral medication , significant clinical deterioration previous 14 day , meet eligibility criterion progress Stage 2 . In Stage 2 patient receive 84 day consolidation therapy ( 56 day study drug 28 day follow-up ) . On outpatient basis , patient receive either placebo 1 2 dos rIFN-gamma 1b sc 3 time per week , oral fluconazole daily oral itraconazole 2 time day .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Cryptococcal</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Flucytosine</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible Stage 1 : Are least 13 year old . Have consent parent , family member , guardian less 18 year age . Have cryptococcal meningitis first time relapse . Are medication take fluconazole itraconazole , patient trouble take fluconazole . Patients may eligible Stage 2 : Had serious decline health , determine doctor , previous 14 day ( include mental health ) . Have receive least 7.5 mg/kg AMB Stage 1 . Have positive CSF culture C. neoformans . Can take oral medication . Exclusion Criteria Patients eligible study : Are coma . Are pregnant breastfeeding . Are use effective birth control method , able child . Are allergic imidazole triazole . Are allergic rIFNgamma 1b . Require drug toxic kidney , AMB . Received erythropoietin red blood cell transfusion within 4 week enter study . Are receive systemic corticosteroid therapy within 30 day study require study . Have serious heart disease . Have multiple sclerosis , peripheral vascular disease , rheumatologic disorder . Have disorder central nervous system ( CNS ) ( include emotional problem ) seizure disorder , current CNS disorder would interfere study . Are receive investigational therapy C. neoformans within 90 day start study drug . Have 3 dos AMB 1200 mg fluconazole itraconazole prior treatment begin current treatment 72 hour prior start study medication . Fluconazole itraconazole 200 mg daily allow . Are receive AMB C. neoformans within 30 day start treatment present episode . Are receive rIFNgamma 1b treatment within 90 day prior start study drug . Have therapy affect immune system within 30 day prior start study drug . Are receive investigational therapy sign within 30 day prior start study drug . Are able meet study requirement , opinion investigator . Require chronic treatment H2blockers , able receive itraconazole Stage 2 . Show sign get treatment another serious opportunistic infection within 4 week start study drug .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Interferon-gamma , Recombinant</keyword>
	<keyword>Injections , Subcutaneous</keyword>
	<keyword>Itraconazole</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Flucytosine</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Amphotericin B</keyword>
	<keyword>Meningitis , Cryptococcal</keyword>
</DOC>